In this regard, a diversified therapeutic T cell repertoire that reacts against TME antigens beyond tumor-associated antigens conceptually and operationally affords host protection against cancer cells that represent antigen- or MHC-loss variants, which might otherwise evade T cell surveillance strictly directed against intrinsic tumor antigens [9,34]. This evidence concerns the gene HLA-C and neoplasm.